During MAPK-targeted therapy, tumor cells activate drug resistance-related pathways, such as the MAPK, PI3K-mTOR, and Wnt pathways, which results in the loss of MHC-I molecules and dampening the antitumor immune response. Here, MTOR is linked to neoplasm.